Generalizing the results of clinical trials to actual practice: The example of clopidogrel therapy for the prevention of vascular events

American Journal of Medicine

Volumn 107, Issue 6, 1999, Pages 568-572

  Caro, J Jaime ^a,b   Migliaccio Walle, Kristen ^a  

^a CARO RESEARCH INSTITUTE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTERY DISEASE; ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REDUCTION; RISK ASSESSMENT;

AGED; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; BRAIN ISCHEMIA; CLINICAL TRIALS; COHORT STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK; SASKATCHEWAN; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0032806356     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00295-8     Document Type: Article

References (16)

1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339.
2. Chatellier G., Zapletal E., Lemaitre D., et al. The number needed to treat a clinically useful nomogram in its proper context . BMJ. 312:1996;426-429.
3. Cook R.J., Sackett D.L. The number needed to treat a clinically useful measure of treatment effect . BMJ. 310:1995;452-454.
4. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. NEJM. 318:1988;1728-1733.
5. Rajkumar S.V., Sampathkumar P., Gustafson A.B. Number needed to treat is a single measure of treatment efficacy for clinicians. J Gen Intern Med. 11:1995;357-359.
6. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. II. Short-term reductions in blood pressure overview of randomised drug trials in their epidemiological context . Lancet. 335:1990;827-838.
7. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertension. 17:1999;151-183.
8. Button A., McKee M., Black N., et al. Threats to applicability of randomised trials exclusions and selective participation . J Health Serv Res Policy. 4:1999;112-121.
9. Tabar L., Fagerberg G., Duffy S.W., et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am. 30:1992;187-210.
10. Malcolm E., Downey W., Strand L.M., et al. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Marketing Surveillance. 6:1993;175-264.
11. Stergachis A., Sheingold S., Luce B.R., et al. Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med. 152:1992;1220-1224.
12. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
13. Fleiss J.L. Statistical Methods for Rates and Proportions. 2nd ed. 1981;Wiley, New York.
14. Caro J.J., Flegel K.M., Orejuela M.E., et al. Anticoagulant prophylaxis against stroke in atrial fibrillation effectiveness in actual practice . Can Med Assoc J. 161:1999;493-497.
15. Andrade S.E., Wallier A.M., Gottlrib L.K., et al. Discontinuation of antihyperlipidemic drugs. Do rates reported in clinical trials reflect rates in primary care settings? NEJM. 332:1995;1125-1131.
16. Caro J.J., Speckman J.L., Salas M., et al. Effect of initial drug choice on persistence with antihypertensive therapy the importance of actual practice data . Can Med Assoc J. 160:1999;41-46.